Seeta Trivedi, MD
Medical Oncology · Edison, NJNPI 1295962728
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,583 of the $5,938 with a category attached, or 60.3%. 33 manufacturers reported payments, led by Daiichi Sankyo Inc. at 26.0% of the total. Reporting peaked in 2022 at $3,175 and has fallen 96.0% since, to $128 in 2025.
Across 71 payments — averaging $83.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$2K
- E.r. Squibb & Sons, L.L.C.$1K
- Stemline Therapeutics Inc.$920
- Amgen$299
- AstraZeneca$193
- Novartis$131
- plus $1K from 27 others
Across 2 payments — averaging $80.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$161
What the payments were for
- Consulting fees$3,58360%
- Food & beverage$1,86631%
- Education$4898%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 3 | $1,542 |
| E.r. Squibb & Sons, L.L.C. | 4 | $1,487 |
| Stemline Therapeutics Inc. | 1 | $920 |
| Amgen | 4 | $299 |
| AstraZeneca(2 entities) | 5 | $193 |
| Novartis | 6 | $131 |
| Exelixis Inc. | 1 | $128 |
| Epizyme, Inc. | 1 | $125 |
| Karyopharm Therapeutics Inc. | 1 | $125 |
| Seagen Inc. | 2 | $112 |
| Johnson & Johnson | 1 | $100 |
| Blueprint Medicines Corporation | 1 | $93 |
| Bristol Myers Squibb | 5 | $79 |
| Pfizer | 4 | $78 |
| AbbVie | 3 | $50 |
| Janssen Scientific Affairs, LLC | 3 | $50 |
| Eisai Inc. | 3 | $47 |
| Mirati Therapeutics, Inc. | 2 | $44 |
| Gilead | 3 | $40 |
| Pharmacosmos Therapeutics Inc. | 2 | $37 |
| Astellas Pharma US Inc | 2 | $34 |
| Incyte Corporation | 2 | $31 |
| Puma Biotechnology, Inc. | 2 | $29 |
| Sirtex Medical Inc | 1 | $22 |
| Genentech USA, Inc. | 1 | $21 |
| Merck | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Spectrum Pharmaceuticals Inc. | 1 | $16 |
| Sanofi | 1 | $15 |
| Clovis Oncology, Inc. | 1 | $14 |
| Boston Scientific | 1 | $13 |
| Lilly USA, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,938 in reported general payments places this provider in the 65th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 30 | $452,124 |
| ImbruvicaIbrutinib | 27 | $414,300 |
| XtandiEnzalutamide | 22 | $314,521 |
| VonjoPacritinib Citrate | 12 | $301,888 |
| Lenalidomide | 18 | $222,234 |
| NeulastaPegfilgrastim | 26 | $186,007 |
| KeytrudaPembrolizumab | 16 | $179,127 |
| Somatuline DepotLanreotide Acetate | 13 | $124,622 |
| Lupron DepotLeuprolide Acetate | 21 | $119,391 |
| AranespDarbepoetin Alfa In Polysorbat | 55 | $113,120 |
| ProcritEpoetin Alfa | 88 | $108,311 |
| EliquisApixaban | 145 | $102,442 |
| OntruzantTrastuzumab-Dttb | 17 | $63,359 |
| VenclextaVenetoclax | 18 | $44,355 |
| XareltoRivaroxaban | 27 | $34,922 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $79 | $452,12430 claims |
| Astellas Pharma US IncXtandi | $34 | $314,52122 claims |
| AmgenNeulasta, Aranesp | $299 | $299,12781 claims |
| MerckKeytruda | $19 | $179,12716 claims |
| AbbVieLupron Depot, Venclexta | $50 | $163,74639 claims |
| Johnson & JohnsonProcrit, Xarelto | $100 | $143,233115 claims |
| PfizerEliquis | $78 | $102,442145 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 112 medical oncology providers in New Jersey.
Other medical oncology in Edison
- James McCloskeyHackensack$2.8M
- Jamie KoprivnikarHackensack$1.7M
- Andrew PecoraHackensack$1.2M
- David VesoleHackensack$726K
- Lori LeslieHackensack$665K
- Noa BiranHackensack$263K
- Robert AlterHackensack$232K
- Harry HarperHackensack$226K
- Tatyana FeldmanHackensack$193K
- David SiegelHackensack$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.